Actavis launches generic ondansetron in USA

8 July 2007

Iceland-headquartered generic drug group Actavis says that it has launched its ondansetron tablets in the U.S. Actavis will market the product under an agreement with Natco Pharma. Distribution of the product will commence immediately.

Ondansetron HCl, the generic equivalent of UK drug major GlaxoSmithKline's Zofran, will be available in 4mg and 8mg strengths. The product is indicated for prevention of nausea and vomiting caused by cancer chemotherapy, radiation therapy and surgery.

Annual sales of ondansetron tablets in the USA were around $746.0 million for the 12 months ending March 2007 according to IMS Health data.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Company News Directory

Companies featured in this story

More ones to watch >

Today's issue

Company Spotlight

Ginkgo Bioworks

Ginkgo Bioworks is headquartered in Boston, Massachusetts, where it operates its central “Foundry” for high-throughput cell engineering. The company supports partners globally across biopharma, agriculture, industrial biotechnology, and biosecurity through its Boston-based infrastructure and distributed digital platforms.